Profile data is unavailable for this security.
About the company
Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.
- Revenue in JPY (TTM)355.69m
- Net income in JPY-764.60m
- Incorporated2017
- Employees56.00
- LocationCuorips Inc507,Nihonbashi Life Science Bldg. 2, 3-11-5,CHUO-KU 103-0023JapanJPN
- Phone+81 362310043
- Websitehttps://cuorips.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daito Pharmaceutical Co Ltd | 51.20bn | 2.23bn | 41.11bn | 1.07k | 18.35 | 0.7746 | 6.20 | 0.803 | 74.42 | 74.42 | 1,703.91 | 1,763.62 | 0.6544 | 2.16 | 2.76 | 47,716,680.00 | 2.90 | 5.12 | 3.71 | 6.67 | 17.63 | 21.75 | 4.43 | 7.35 | 1.31 | -- | 0.1739 | 24.48 | 7.99 | 2.39 | -42.09 | -13.52 | 20.45 | 14.00 |
| Fuji Pharma Co Ltd | 54.57bn | 2.33bn | 56.00bn | 1.76k | 23.57 | 1.15 | 8.90 | 1.03 | 95.46 | 95.46 | 2,233.29 | 1,959.48 | 0.5765 | 1.49 | 2.83 | 31,007,950.00 | 2.46 | 4.51 | 3.93 | 6.76 | 40.82 | 40.57 | 4.27 | 8.51 | 0.876 | 17.58 | 0.3885 | 25.98 | 12.01 | 8.87 | -51.19 | 7.55 | 8.07 | 7.94 |
| ASKA Pharmaceutical Holdings Co Ltd | 68.70bn | 4.91bn | 69.12bn | 1.63k | 13.90 | 0.9927 | 8.92 | 1.01 | 172.92 | 172.92 | 2,421.07 | 2,420.68 | 0.6729 | 1.37 | 3.62 | 42,094,980.00 | 4.93 | 5.50 | 6.64 | 7.07 | 48.33 | 47.56 | 7.32 | 7.98 | 1.23 | 75.35 | 0.1551 | 16.60 | 2.06 | 4.07 | -32.39 | 51.04 | 9.49 | 31.48 |
| Oncolys Biopharma Inc | 28.55m | -2.06bn | 71.47bn | 35.00 | -- | 17.86 | -- | 2,503.73 | -80.66 | -80.66 | 1.11 | 136.64 | 0.0074 | 0.00 | 0.1004 | -- | -53.08 | -53.26 | -58.54 | -60.19 | 0.00 | -- | -7,209.58 | -484.93 | 9.54 | -424.60 | 0.0741 | -- | -9.04 | -38.10 | -22.16 | -- | 2.22 | -- |
| Cuorips Inc | 355.69m | -764.60m | 78.11bn | 56.00 | -- | 15.56 | -- | 219.59 | -93.30 | -93.30 | 43.60 | 607.39 | 0.0656 | 3.33 | 238.00 | 6,351,607.00 | -14.20 | -- | -14.62 | -- | 76.69 | -- | -216.57 | -- | 36.81 | -- | 0.00 | -- | 658.40 | -- | -1.92 | -- | -- | -- |
| Nxera Pharma Co Ltd | 28.70bn | -6.14bn | 78.55bn | 374.00 | -- | 1.20 | -- | 2.74 | -68.13 | -68.13 | 318.44 | 725.52 | 0.1936 | 1.47 | 4.57 | 76,737,970.00 | -4.14 | -1.71 | -4.63 | -1.85 | 71.17 | 84.07 | -21.41 | -10.93 | 2.55 | -11.73 | 0.4902 | -- | 125.87 | 24.28 | 32.74 | -- | 40.57 | -- |
| JCR Pharmaceuticals Co Ltd | 37.55bn | -2.44bn | 85.46bn | 987.00 | -- | 1.74 | 183.79 | 2.28 | -19.98 | -19.98 | 307.86 | 379.76 | 0.3432 | 0.4534 | 2.50 | 38,039,510.00 | -2.21 | 5.86 | -3.77 | 9.33 | 70.45 | 73.83 | -6.45 | 13.60 | 0.668 | -- | 0.5295 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Kyorin Pharmaceutical Co Ltd | 133.26bn | 10.77bn | 99.87bn | 2.00k | 8.89 | 0.6892 | 6.49 | 0.7495 | 187.40 | 187.40 | 2,319.59 | 2,417.37 | 0.6927 | 1.08 | 2.93 | 66,695,200.00 | 5.60 | 3.34 | 7.03 | 4.16 | 45.32 | 45.89 | 8.08 | 5.11 | 2.05 | -- | 0.1746 | 57.34 | 8.83 | 3.41 | 70.73 | 8.12 | 14.36 | -7.06 |
| Katakura Industries Co Ltd | 40.98bn | 5.84bn | 106.53bn | 941.00 | 16.59 | 1.06 | 12.11 | 2.60 | 182.30 | 182.30 | 1,278.51 | 2,853.06 | 0.2926 | 2.15 | 6.42 | 43,545,160.00 | 4.27 | 2.60 | 5.20 | 3.57 | 36.16 | 37.98 | 14.59 | 9.44 | 2.63 | -- | 0.0807 | 23.42 | -1.37 | -2.19 | 15.73 | 15.27 | -7.22 | 33.03 |
| Zeria Pharmaceutical Co Ltd | 86.61bn | 7.26bn | 113.33bn | 1.75k | 13.45 | 1.02 | 7.79 | 1.31 | 164.79 | 164.79 | 1,964.97 | 2,178.21 | 0.5366 | 1.27 | 3.21 | 49,607,640.00 | 4.49 | 4.67 | 6.99 | 7.47 | 72.76 | 72.17 | 8.37 | 9.02 | 0.9739 | 11.41 | 0.2984 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
Data as of Feb 13 2026. Currency figures normalised to Cuorips Inc's reporting currency: Japanese Yen JPY
0.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Simplex Asset Management Co., Ltd.as of 08 Jan 2026 | 17.00k | 0.21% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 2.40k | 0.03% |
| Global X Japan Co., Ltd.as of 08 Jan 2026 | 400.00 | 0.01% |
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
